Supplementary Data — Artemisinin reduces COVID-19 risk: real-time meta-analysis of 3 studies

@CovidAnalysis, October 2026, Version 1V1

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

October 2026

Artemisinin COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Trieu (RCT)52%0.48 · 0.22–1.06no recov.8/399/21ARTI-19 Chandiwana (RCT)−152%2.52 · 0.11–60.46hosp.1/750/39CT¹ Chandiwana (RCT)29%0.71 · 0.17–3.04progression39 (n)39 (n)CT¹ Chandiwana (RCT)−31%1.31 · 0.29–5.59progression39 (n)39 (n)CT¹ Chandiwana (RCT)71%0.29 · 0.04–2.06progression36 (n)39 (n)CT¹ Chandiwana (RCT)27%0.73 · 0.51–1.06recov. time39 (n)39 (n)CT¹ Chandiwana (RCT)22%0.78 · 0.46–1.30recov. time39 (n)39 (n)CT¹ Chandiwana (RCT)31%0.69 · 0.41–1.18recov. time36 (n)39 (n)CT¹ Chandiwana (RCT)−1%1.01 · 0.95–1.08viral load39 (n)37 (n)CT¹ Chandiwana (RCT)−5%1.05 · 1.01–1.09viral load39 (n)37 (n)CT¹ Chandiwana (RCT)2%0.98 · 0.94–1.01viral load36 (n)37 (n)CT¹ Chandiwana (RCT)−34%1.34 · 0.87–2.07viral+39 (n)38 (n)CT¹ Chandiwana (RCT)−25%1.25 · 0.68–2.27viral+24/3925/38CT¹ Chandiwana (RCT)−45%1.45 · 0.78–2.70viral+23/3325/38CT¹ Lin31%0.69 · 0.50–0.95recov. time18 (n)25 (n) Lin28%0.72 · 0.52–0.99recov. time18 (n)25 (n) Lin17%0.83 · 0.70–0.99recov. time18 (n)25 (n) Lin8%0.92 · 0.80–1.05hosp. time18 (n)25 (n) Lin29%0.71 · 0.50–1.01viral time18 (n)25 (n)

00.511.52+

¹ CT: study uses combined treatment

Rotate screen for more detailsIncrease width for more details

← Artemisinin
reduces riskArtemisinin
increases risk →

Fig. S1. All outcomes.

Loading..

Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.